Standard Biotools (LAB) Shares Outstanding (Weighted Average) (2010 - 2026)

Standard Biotools (LAB) has 17 years of Shares Outstanding (Weighted Average) data on file, last reported at $388.2 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $388.2 million, up 2.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $388.2 million (up 2.64% YoY), and the FY2025 annual result was $381.6 million, up 8.03% from the prior year.
• Shares Outstanding (Weighted Average) rose to $388.2 million in Q1 2026 per LAB's latest filing, from $381.6 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $388.2 million in Q1 2026 and troughed at $77.0 million in Q1 2022.
• A 5-year average of $228.7 million and a median of $294.1 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Weighted Average) climbed 0.09% in 2023, then jumped 370.5% in 2024.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $78.3 million in 2022, then increased by 1.09% to $79.2 million in 2023, then soared by 346.24% to $353.2 million in 2024, then increased by 8.03% to $381.6 million in 2025, then climbed by 1.72% to $388.2 million in 2026.
• Business Quant data shows LAB's Shares Outstanding (Weighted Average) at $388.2 million in Q1 2026, $381.6 million in Q4 2025, and $380.5 million in Q3 2025.